View Cart

LumiThera Inc. to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)

SEATTLE, March 13, 2018 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announces that Clark E. Tedford, Ph.D., Chief Executive Officer, is scheduled to present on Saturday, March 17, 2018 at 9:30 a.m. China Standard Time, at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS) in Hangzhou, China.

“We are excited to present at this innovative healthcare conference that is focused on building cross-border relationships between Chinese and Western Healthcare investors and companies. This conference provides us a unique opportunity to receive updates on the regulatory environment, establish successful global partnerships and meet with active Asian investors,” said Clark E. Tedford, Chief Executive Officer, LumiThera Inc.

The China Healthcare Investment & Partnering Symposium is hosted by TPP Healthcare and supported by a leading investment bank B.Riley FBR.

A live webcast including audio and slides can be accessed at http://wsw.com/webcast/brileyco20/lumi.

For more information on the conference agenda, please access:
https://www.meetmax.com/sched/event_47969/~public/conference_home.html

About LumiThera Inc.
LumiThera, Inc. is a clinical stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company’s is the leader in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments.

SOURCE LumiThera Inc.

Leave a reply

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> 

required